Portola Phramaceuticals (PTLA)

[H2R]

PTLA will target a large number of hospitals

Now that the PAS is approved, the CC comments can be taken more seriously.

So we expect that to continue next year as we target more accounts. So going into the second part of your question, in terms of the Gen 2 rollout, we're - we have multiple tiers. And we've I think discussed this a little bit previously. The tier 1 or our first set of targets are about 600 U.S. hospitals are Level I or Level II trauma centers or have Comprehensive Stroke designation. So those are the biggest institutions across the country. The next tier of about 900 additional accounts, additional hospitals were the Advanced Stroke Center designation.

So those are all pretty important accounts for us. And then finally, from what we've seen in the Early Supply Program, we also want to be able to stock affiliates of these accounts too, because oftentimes patients might present to an affiliate account. That's where we want the drug to get started, if they're showing up there. And then they're transferred to the larger account. So we'll be going on next year to target as many as we can.

Scott Garland, CEO

https://seekingalpha.com/article/4219652-portola-pharmaceuticals-ptla-ceo-scott-garland-q3-2018-results-earnings-call-transcript?part=single

This is to pair up with today's PR:

Full Commercial Launch to Begin January 2019

http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2381753

I do expect a very good stock performance in 2019